Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Tuesday, October 4, 2011

TMAU mentioned in popular UK fiction drama show 'Doc Martin' last night

Last night Trimethylaminuria was mentioned in a new episode of the popular doctor fiction drama show in the UK, Doc Martin. The series screens at peak evening viewing time on the popular ITV channel. Last nights show (it's first screening), called 'Mother knows best' included a short filler scene where a young man was at the Dr's surgery with a 'fishy smell'. Doc Martin told him he suspected TMAU and asked for a urine sample. That was basically it.

Whoever did the research on TMAU seemed to have got the current facts slightly mixed up. They were confusing trimethylamine with tyramine. At one point the Dr said it was tyramine that caused the smell. He asked the patient if cheese made his pulse race, cheese often being high in tyramine. Ironically tyramine is associated with the FMO3 enzyme, likely being a pathway to partly detoxify tyramine. High tyramine levels have been associated with migraines, though this does not seem to be consensually agreed. It can also be found in foods such as cheese and chocolate. Dr Eileen Treacy did some research a number of years ago to see if people with FMO3 deficiency tended to have high blood pressure, the theory being high levels of circulating catecholamine releasing agents (such as tyramine) can raise blood pressure, but it was found not to be so. Nevertheless, in theory it may be suspected that people with FMO3 deficiency may be sensitive to catecholamines (if they use the FMO3 enzyme for detoxification) until consensus shows this is not so.

So even though the researcher for the show got their facts confused, perhaps they are right about tyramine and raised pulses with FMO3 deficiency afterall !

Eileen Treacy 2005 Hypertension study in Ireland

2000 paper on FMO3 and tyramine by Cashman, Treacy et al

Consistent with the fact that human drug-metabolizing enzymes have endogenous substrates and are prevalent not as neutral balanced polymorphisms but for their selective advantages, we have previously shown that human FMO3 metabolizes biogenic amines such as tyramine and phenethylamine, resulting in formation of their oxime metabolites. Formation of oxime metabolites generally terminates the pharmacological activity of the parent amine (Lin and Cashman, 1997a,b). Herein, we show that the methionine variant at codon 257 of human FMO3 shows decreased N-oxygenation for the substrate tyramine. Tyramine is an indirectly acting sympathomimetic that exerts its pressor effect through amine uptake into the sympathetic nervous system with release of norepinephrine from synaptic vesicles. It is thus possible that human FMO3 polymorphisms affecting tyramine or other biogenic amine metabolism may predispose humans to variable tolerance to tyramine or other biogenic amine-containing foods and the associated symptoms (Reddy and Hayes, 1989; Stratton et al., 1991).

Quote from Nigel Manning TMAU PDF for Sheffield Children's Hospital

TMAU1 patients may suffer from adverse drug reactions (eg with codeine;
tamoxifen; ketoconazole; nicotine; cimetidine; ranitidine; phenothiazine).
Hypertension may result from ingestion of red wine and cheese (and
chocolate), which produce the neurotransmitter tyramine, another FMO3
dependent compound. Many people suffer from migraines associated with
tyramine containing foods and perhaps FMO3 deficiency may explain some of
these cases, but overall this demonstrates the adverse medical
consequences as well as the odour related psychosocial aspects.

wikipedia : tyramine


Post a Comment